Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Zacks Research

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) was upgraded by Zacks Research from a "hold" rating to a "strong-buy" rating in a report released on Monday,Zacks.com reports.

A number of other research firms also recently issued reports on MNPR. Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday, June 2nd. Chardan Capital reiterated a "buy" rating and issued a $100.00 target price on shares of Monopar Therapeutics in a research report on Monday, March 30th. BTIG Research lifted their price objective on Monopar Therapeutics from $104.00 to $117.00 and gave the company a "buy" rating in a research note on Tuesday, June 30th. UBS Group set a $105.00 price objective on shares of Monopar Therapeutics in a report on Monday, June 29th. Finally, Wall Street Zen downgraded shares of Monopar Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday. Three equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Monopar Therapeutics presently has an average rating of "Buy" and an average target price of $108.75.

Monopar Therapeutics Stock Down 3.4%

NASDAQ MNPR opened at $99.79 on Monday. Monopar Therapeutics has a twelve month low of $29.18 and a twelve month high of $112.57. The business has a 50-day moving average price of $72.95 and a 200-day moving average price of $64.26. The firm has a market cap of $668.59 million, a price-to-earnings ratio of -52.52 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.41. Research analysts expect that Monopar Therapeutics will post -2.82 EPS for the current fiscal year.

Institutional Trading of Monopar Therapeutics

A number of hedge funds have recently added to or reduced their stakes in MNPR. Goldman Sachs Group Inc. purchased a new stake in shares of Monopar Therapeutics during the 1st quarter worth approximately $673,000. Jane Street Group LLC purchased a new stake in shares of Monopar Therapeutics in the first quarter valued at $377,000. Geode Capital Management LLC grew its stake in shares of Monopar Therapeutics by 99.7% in the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company's stock valued at $3,468,000 after buying an additional 48,379 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after purchasing an additional 1,821 shares in the last quarter. Finally, Rhumbline Advisers acquired a new stake in shares of Monopar Therapeutics during the second quarter valued at about $209,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.